Clustered 10b5-1 plan adoptions at Wave Life Sciences, normal or notable?

I’m looking for feedback from people who’ve looked at insider trading patterns before.

Wave Life Sciences (WVE) stock jumped \~3x on December 8 following positive interim trial results. On that same day, 8 executives/directors executed stock sales under 10b5-1 plans. I understand the same-day execution is plausibly explained by price-based triggers or limit orders.

However, I saw that the 8 plans that executed on December 8 were initiated in two clusters:

* 3 plans on March 13, 2025
* 5 plans on August 6, 2025

I pulled Form 4 data for Wave from 2024–2025 to look closer at this pattern and wrote up the details here [https://rxdatalab.com/research/wave-life-sciences-insiders/](https://rxdatalab.com/research/wave-life-sciences-insiders/)

My question:
I'm relatively new to this. Is this kind of clustered 10b5-1 adoption and execution fairly typical in biotech or other industries? Is this easily explained by compensation cycles/normal planning, or is this something you’d flag as worth a second look?

I haven't yet benchmarked against a larger sample of biotech companies, that's on my list if this is indeed notable.